Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: Impact of cannabis use-Reference-Cited by-同舟云学术

Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: Impact of cannabis use

Published:2007-08 Issue:1-3 Volume:94 Page:29-36
ISSN:0920-9964
Container-title:Schizophrenia Research
language:en
Short-container-title:Schizophrenia Research

Author:

Leweke F. Markus,Giuffrida Andrea,Koethe Dagmar,Schreiber Daniela,Nolden Brit M.,Kranaster Laura,Neatby Miriam A.,Schneider Miriam,Gerth Christoph W.,Hellmich Martin,Klosterkötter Joachim,Piomelli Daniele

Publisher

Elsevier BV

Subject

Biological Psychiatry,Psychiatry and Mental health

Reference42 articles.

1. Diagnostic and statistical manual of mental disorders;American Psychiatric Association,1994

2. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts;Andreasson;Lancet,1987

3. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study;Arseneault;Br. Med. J.,2002

4. Causal association between cannabis and psychosis: examination of the evidence;Arseneault;Br. J. Psychiatry,2004

5. Prenatal exposure to a cannabinoid receptor agonist does not affect sensorimotor gating in rats;Bortolato;Eur. J. Pharmacol.,2006

Cited by 210 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Conclusion;Anandamide in Health and Disease;2025

2. Anandamide in disease: Role in psychosis;Anandamide in Health and Disease;2025

3. A brief review of anandamide in cannabis use and cannabis use disorder;Anandamide in Health and Disease;2025

4. Imaging the endocannabinoid enzyme fatty acid amide hydrolase in the living human brain;Anandamide in Health and Disease;2025

5. Endocannabinoid system alterations in schizophrenia: association with cannabis use and antipsychotic medication;European Archives of Psychiatry and Clinical Neuroscience;2024-03-19